Clinical Trials List
2023-05-29 - 2027-01-31
Phase II
Recruiting3
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- MING-YANG WANG Division of General Surgery
- 張端瑩 Division of Hematology & Oncology
- 黃柏翔 Division of Hematology & Oncology
- 林季宏 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 蔡立威 Division of General Surgery
- 李佳真 Division of Hematology & Oncology
- 郭文宏 Division of General Surgery
- 楊明翰 Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- 羅喬 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
60 participants
